Immuneering Corporation
3 clinical trials · Sponsor
◉ Watch Immuneering Corporation
| Record | Firm | Date |
|---|---|---|
| Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (NCT07562152) | Immuneering Corporation | 2026-06-05 |
| A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors (NCT06208124) | Immuneering Corporation | 2024-02-27 |
| A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors (NCT05585320) | Immuneering Corporation | 2022-10-31 |
Track Immuneering Corporation automatically
Every clearance here is in the API, with alerts when new ones post.